STN: sBLA 125057/196

Dear Dr. Peterson:

Please refer to your supplemental biologics license application dated and received September 3, 2009, submitted under section 351 of the Public Health Service Act for HUMIRA® (adalimumab).

We acknowledge receipt of your submissions dated October 28 and 29, and November 13, 2009.

Reference is also made to an FDA letter dated August 4, 2009 notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for HUMIRA (adalimumab). This information pertains to the risk of malignancies in pediatric patients, leukemia in adults, and psoriasis-like lesions associated with use of products within the class of TNF-blockers.

Your supplemental biologics license application provides for revisions to the labeling for HUMIRA (adalimumab), consistent with our August 4, 2009, letter, and correspondences dated October 16, 26, 28, 30 (2), and November 4, 2009.

We have completed our review of this application, as amended, and it is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

Your approved Medication Guide will become part of the proposed Risk Evaluation and Mitigation Strategy (REMS) revisions submitted as pending supplement STN BL125057.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format as described at http://www.fda.gov/oc/datacouncil/spl.html that is identical to the attached labeling and Medication Guide. For administrative purposes, please designate this submission, “SPL for approved BLA 125057/196.” In addition, within 21 days of the date of this letter, amend any
pending supplement(s) for this BLA with content of labeling in SPL format to include the changes approved in this supplement.

We request that the revised labeling approved today be available on your website within 10 days of receipt of this letter.

Marketing the product with labeling that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

**LETTER TO HEALTH CARE PROFESSIONALS**

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this BLA and a copy to the following address:

MEDWATCH  
Food and Drug Administration  
Suite 12B-05  
5600 Fishers Lane  
Rockville, MD 20857

This information will be included in your biologics license application file.

If you have any questions, please contact Christopher Hilfiger, Regulatory Health Project Manager, at (301) 796-4131.

Sincerely,

/Larissa Lapteva/

Larissa Lapteva, M.D., M.H.S.  
Deputy Director for Safety  
Division of Anesthesia, Analgesia  
and Rheumatology Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

Enclosures (2):  
Package Insert  
Medication Guide